Abbott Laboratories stock
Price history
−16.05% over the period1 year: from $129.26 (November 13, 2025) to $108.52 (November 13, 2026), −16.05%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $108.52 |
| October 30, 2026 | $106.20 |
| September 30, 2026 | $98.83 |
| August 31, 2026 | $110.36 |
| July 31, 2026 | $105.70 |
| June 30, 2026 | $90.74 |
| May 29, 2026 | $85.60 |
| April 30, 2026 | $90.79 |
| March 31, 2026 | $102.67 |
| February 27, 2026 | $116.35 |
| January 30, 2026 | $109.30 |
| December 31, 2025 | $125.29 |
| November 28, 2025 | $128.90 |
| November 13, 2025 | $129.26 |
At a glance
The company
Discover, develop, manufacture and sell pharmaceutical, diagnostic, nutritional and medical device products globally
Latest results
Quarter to September 30, 2026 · EPS $1.42 (estimate $1.42)
Next event
TickerLandia's take on Abbott Laboratories
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 29 vs a median of 38 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 40 vs 31 (+29%) in a group of 11.
- Strong point: Dividend (82/100 in its group). Weak point: Profitability (35/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−17.81% from the 52-week high
Analysts · 28 analysts
Average target$118.91+9.57% vs. price
Buy 23 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Abbott Laboratories
Compared with similar companies: very high dividend.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage59
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 40.5 74 Forward P/E 18.3 35 EV/EBITDA 18.8 72 Price/book 3.68 50 Price/sales 3.90 66 Profitabilitylow35
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 15.6% 44 Gross margin 57.2% 37 ROA 4.9% 24 ROE 9.1% 27 Net margin 9.7% 40 Earnings stabilityhigh63
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.6% 69 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthlow36
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −43.60% 15 Average revenue growth (3 years) +0.51% 18 Revenue growth (year over year) +14.50% 76 Financial strengthaverage43
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.47 57 Debt/equitycounts in reverse: lower means more financial strength 0.61 37 Current ratio 1.46 31 Interest coverage 18.1 48 Dividendvery high82
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 96 Dividend yield 2.3% 69 Payout ratio 94.0% 80 Market momentumaverage52
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −16.05% 14 Distance from 200-day average +6.86% 60 Relative strength (3 months) +0.59% 48 Relative strength (6 months) +27.44% 84 Risklow39
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.2% 28 Maximum drawdown (12 months) 36.8% 68 Beta (1 year) 0.07 20
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Abbott Laboratories is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Abbott Laboratories's P/E today is 29.2, below the median of its last 10 fiscal years (38.3; between 14.8 and 211.4 from 2016 to 2025). Abbott Laboratories's P/E (trailing 12 months): 40.5, +29% against the median of a group of 11 similar companies (31.4).
Compared with 11 similar companies
| Metric | Abbott Laboratories | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 40.5 | High | |
| Forward P/E | 18.3 | Middle | |
| Operating margin | 15.6% | Low | |
| ROE | 9.1% | Low | |
| Debt/equity | 0.61 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Abbott Laboratories. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$13.01B
Latest quarter · Q3 2026
Net income
$920M
Latest quarter · Q3 2026
Quarterly net margin
7.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $187.95B
- P/E
- 40.5
- EPS
- $2.68
- Volume
- 6.18M
- Daily trading
- €911.89M
- Dividend yield
- 2.32%
- Last ex-dividend on October 15, 2026
How Abbott Laboratories is changing
All resultsRevenue grew 5.1% a year on average over the last 5 years
Free cash flow equal to 73% of net income
Returns
Abbott Laboratories returns with dividends
$1,000 invested in Abbott Laboratories 5 years ago, on November 15, 2021, would be worth $926 today with dividends reinvested: −7.38% in total, −1.52% per year. On price alone it would be $838 (−16.16%).
| Period | Abbott Laboratories | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +5.76% | −3.12% | $1,058 |
| 6 months | +29.45% | +1.58% | $1,295 |
| Year to date | −13.38% | +10.46% | $866 |
| 1 year | −13.98% | +12.23% | $860 |
| 3 years | +20.68% | +71.41% | $1,207 |
| 5 years | −7.38% | +61.48% | $926 |
| 10 years | +234.00% | +249.40% | $3,340 |
Over the last 6 months it has done better than 67% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Abbott Laboratories: technical analysis
Abbott Laboratories shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 23.3% below its highest close since January 2, 1990 ($141.46, December 27, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- +6.86%
Support and resistance
Price areas where Abbott Laboratories has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$121.77+12.21%3 touches, last on January 5, 2026
- Resistance$117.08+7.88%3 touches, last on November 5, 2026
- Resistance$110.61+1.93%2 touches, last on July 29, 2026
- Last price$108.52
- Support$104.55−3.66%3 touches, last on September 22, 2026
- Support$100.61−7.29%2 touches, last on September 17, 2026
- Support$97.90−9.78%2 touches, last on October 21, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.07
- Volatility (60 sessions, annualised)
- 26.2%
- Largest fall in the last year
- −36.78%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Abbott Laboratories: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Abbott Laboratories has been November: +2.12% on average, positive in 26 years out of 36. The weakest has been August: −0.23% on average, positive in 23 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.15% | −0.18% | 18 of 36 |
| February | +0.62% | +1.34% | 20 of 37 |
| March | −0.18% | −0.22% | 18 of 37 |
| April | +1.75% | +1.26% | 23 of 37 |
| May | +1.30% | +1.48% | 23 of 37 |
| June | +0.19% | +0.73% | 21 of 37 |
| July | +1.99% | +2.10% | 24 of 37 |
| August | −0.23% | +0.70% | 23 of 37 |
| September | +0.84% | +0.65% | 21 of 37 |
| October | +1.76% | +1.86% | 23 of 37 |
| November | +2.12% | +3.02% | 26 of 36 |
| December | +1.24% | +1.26% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Abbott Laboratories and its competitors
With 122,000 employees, the group develops and sells products across four segments: generic pharmaceuticals, anti-infective drugs and influenza vaccines, laboratory and point-of-care diagnostic systems, and nutritional and medical devices. Its diagnostics range includes molecular tests for HIV, SARS-CoV-2, influenza, RSV and strep A, as well as drug and alcohol tests. Its nutritional line covers pediatric and adult formulas and infant formula, while its devices address heart rhythm management, heart failure, vascular and structural heart conditions, neuromodulation and diabetes care through glucose monitoring systems.
- Headquarters
- Abbott Park, United States
- Employees
- 122,000
- Founded
- 1888
- Chief executive
- Robert Ford
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Abbott LaboratoriesABT | $187.95B | 15.6% | 40.5 | +29.45% |
| MedtronicMDT | $131.57B | 20.1% | 25.3 | +34.97% |
| StrykerSYK | $117.88B | 24.0% | 33.0 | +2.50% |
| Boston ScientificBSX | $64.27B | 19.6% | 18.7 | −16.43% |
| Edwards LifesciencesEW | $61.61B | 28.8% | 61.6 | +31.65% |
| GE HealthCare TechnologiesGEHC | $37.54B | 13.8% | 17.6 | +34.14% |
Same industry or related industries, similar size. Compare Abbott Laboratories with its competitors · Full profile
More on Abbott Laboratories
- Abbott Laboratories revenue and financials
- Abbott Laboratories dividend and valuation
- Abbott Laboratories stock return
- Abbott Laboratories employees, headquarters and business
